Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects.
Authors not listed
SIPO Biotechnology Co. Ltd. · 2027
Abstract
This is a first-in-human, randomized, double-blind, placebo-controlled clinical study to evaluate the Safety and Tolerability of SPOT-mRNA01 injection in healthy adult volunteers.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-05-29 MST
Cite this
APA
Anonymous. (2027). A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects. <em>SIPO Biotechnology Co. Ltd.</em>. https://clinicaltrials.gov/study/NCT06567119
Vancouver
Anonymous. A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects. SIPO Biotechnology Co. Ltd.. 2027.
BibTeX
@misc{anon2027ARando,
title = {A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects.},
author = {Anonymous},
journal = {SIPO Biotechnology Co. Ltd.},
year = {2027},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
ENCell 2027
Open access · US-GOV
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
City Therapeutics 2026
Open access · US-GOV
A Phase 1, Randomized, Double-Masked, Placebo-Controlled, Single-Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CITY-RBP4 Administered Subcutaneously in Healthy Volunteers and Participants With Stargardt Disease Type 1 (STGD1)
Tasly Pharmaceutical Group Co., Ltd 2020
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled, Ranibizumab Injected, Multicenter Phase II Clinical Study on the Efficacy and Safety of Sanhuangjingshimingwan in the Wet AMD(Qi and Yin Deficiency, Phlegm-blood Stasis Syndrome )Subjects
CanSino Biologics Inc. 2020
Open access · US-GOV
A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada
Chong Kun Dang Pharmaceutical 2019
Open access · US-GOV
An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects
Shenzhen Kangtai Biological Products Co., LTD 2021
Open access · US-GOV